Huang et al. (31) performed a genome-wide CRISPR-Cas9 screening in glioma cells and found that NF-κB/E2F6 axis is responsible for EGFRvIII-associated TMZ resistance. The gene discussed is NFKB1; the disease is central nervous system cancer.